FRANK E THOMAS
CIK 1242616 · See Remarks · last filed 2026-06-25
FRANK E THOMAS is a corporate insider who has filed 65 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for SPRO, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $136.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$136.2K
6
65
-$2.52M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SPRO | Director | 85,000 | $1.26 | $107.1K | $0 | 12 | 2026-06-25 |
| LRMR | Director | 7,000 | $4.16 | $29.1K | $47.0K | 9 | 2026-05-20 |
| Orchard Therapeutics plc (ORTX) Delisted | See Remarks | 0 | $16.70 | $0 | $7.5K | 13 | 2024-01-24 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Director | — | — | — | $0 | 5 | 2019-06-27 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & COO | 138,195 | — | — | -$2.59M | 21 | 2017-02-27 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | President & CEO | 72,033 | $1.95 | $140.5K | $10.6K | 5 | 2007-08-22 |
Recent Filings
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-25 | SPRO | Grant (A) | +10,000 | $0 | EDGAR |
| 2026-05-20 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2026-03-02 | LRMR | Buy (P) | +5,000 | $25.0K | EDGAR |
| 2025-06-16 | SPRO | Grant (A) | +20,000 | $0 | EDGAR |
| 2025-05-14 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2024-05-30 | SPRO | Grant (A) | +20,000 | $0 | EDGAR |
| 2024-02-15 | LRMR | Buy (P) | +2,000 | $22.0K | EDGAR |
| 2024-01-24 | Orchard Therapeutics plc (ORTX) Delisted | Disp (D) | −92,081 | $0 | EDGAR |
| 2023-10-10 | SPRO | Grant (A) | +20,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.